Single tisagenlecleucel infusion effective in relapsed or refractory B-cell ALL
Michael R. Grunwald, MD, director of the leukemia section in the department of hematologic oncology and blood disorders at the Levine Cancer Institute, Atrium Health, reviews an updated analysis of the phase 2 ELIANA trial, which confirmed the efficacy of a single infusion of the chimeric antigen receptor T-cell therapy tisagenlecleucel among children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Consolidative transplant after CAR T-cell therapy shows promise in certain ALL patients
Michael R. Grunwald, MD, director of the leukemia section in the department of hematologic oncology and blood disorders at the Levine Cancer Institute, Atrium Health, discusses findings from the PLAT-02 trial, which showed that consolidative hematopoietic stem cell transplant after CD19-directed CAR T-cell therapy prolonged leukemia-free survival for certain patients with relapsed or refractory CD19-positive acute lymphoblastic leukemia, particularly those who achieved complete remission after CAR T-cell therapy but remained at risk for relapse with a short term B-cell aplasia derived.
Thank you for participating in this module. Click below to download the certificate.